Cargando…

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report

Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immune-mediated thrombocytopenia are reported. We report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Woo, Hyun Sun, Lee, Kyoung Hwa, Yoon, Phill Hoon, Kim, Su Ji, Park, Inkeun, Kim, Young Saing, Ahn, Hee Kyung, Hong, Junshik, Shin, Dong Bok, Sym, Sun Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4614196/
https://www.ncbi.nlm.nih.gov/pubmed/25544580
http://dx.doi.org/10.4143/crt.2014.052
Descripción
Sumario:Oxaliplatin is a third-generation platinum derivative used for metastatic or advanced colorectal cancer treatment. Although myelosuppression is the most common cause of oxaliplatin-induced thrombocytopenia, rare cases of oxaliplatin-induced immune-mediated thrombocytopenia are reported. We report a case of a 57-year-old woman with colon cancer who developed gum bleeding and petechiae after oxaliplatin infusion. Laboratory tests revealed grade 4 thrombocytopenia and grade 4 neutropenia. She recovered from the thrombocytopenia and accompanying neutropenia within 4 days with no recurrence following discontinuation of oxaliplatin. Physicians need to be aware of the risk of severe acute thrombocytopenia following oxaliplatin administration.